TA
VKTX icon

Tectonic Advisors’s Viking Therapeutics VKTX Stock Holding History

Tectonic Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$188K – 267
2022
Q4 		$188K Buy
+20,000
New +$89.3K 0.03% 231

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tectonic Advisors's VKTX Position: Q1 2023 in Review

Tectonic Advisors sold out of Viking Therapeutics (VKTX) in Q1 2023, closing a stake of 20,000 shares — an estimated $188K sold.

Tectonic Advisors first reported a position in VKTX in Q4 2022 and held it in 1 quarter. The position peaked at $188K in Q4 2022. 184 funds tracked by Wall St. Rank hold VKTX as of Q1 2023.

  • Tectonic Advisors reported no remaining Viking Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tectonic Advisors sold 20,000 Viking Therapeutics shares in Q1 2023, an estimated $188K.
  • Tectonic Advisors first reported a position in Viking Therapeutics in Q4 2022 and held it in 1 quarter.
  • Tectonic Advisors's Viking Therapeutics position peaked at $188K in Q4 2022.
  • 184 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2023.

Based on Tectonic Advisors's 13F filing for Q1 2023, filed 26 Apr 2023.